NZ545498A - Rapid dissolution formulation of a calcium receptor-active compound - Google Patents
Rapid dissolution formulation of a calcium receptor-active compoundInfo
- Publication number
- NZ545498A NZ545498A NZ545498A NZ54549804A NZ545498A NZ 545498 A NZ545498 A NZ 545498A NZ 545498 A NZ545498 A NZ 545498A NZ 54549804 A NZ54549804 A NZ 54549804A NZ 545498 A NZ545498 A NZ 545498A
- Authority
- NZ
- New Zealand
- Prior art keywords
- weight
- composition according
- composition
- hyperparathyroidism
- chosen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- 150000001875 compounds Chemical class 0.000 title description 64
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title description 43
- 239000011575 calcium Substances 0.000 title description 43
- 229910052791 calcium Inorganic materials 0.000 title description 43
- 238000004090 dissolution Methods 0.000 title description 21
- 238000009472 formulation Methods 0.000 title description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 229960000913 crospovidone Drugs 0.000 claims abstract description 17
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 17
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920002472 Starch Polymers 0.000 claims abstract description 14
- 239000008107 starch Substances 0.000 claims abstract description 14
- 235000019698 starch Nutrition 0.000 claims abstract description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 12
- 229940069328 povidone Drugs 0.000 claims abstract description 12
- 201000002980 Hyperparathyroidism Diseases 0.000 claims abstract description 11
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 11
- 208000037147 Hypercalcaemia Diseases 0.000 claims abstract description 8
- 230000000148 hypercalcaemia Effects 0.000 claims abstract description 8
- 208000030915 hypercalcemia disease Diseases 0.000 claims abstract description 8
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims description 56
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 claims description 35
- 229960003315 cinacalcet Drugs 0.000 claims description 35
- 239000008187 granular material Substances 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 4
- 238000009500 colour coating Methods 0.000 claims description 4
- 238000005029 sieve analysis Methods 0.000 claims description 4
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 3
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical compound Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 19
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- 239000008186 active pharmaceutical agent Substances 0.000 description 14
- 238000005469 granulation Methods 0.000 description 14
- 230000003179 granulation Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000007922 dissolution test Methods 0.000 description 10
- 229940032147 starch Drugs 0.000 description 10
- -1 CONH2i CN Chemical compound 0.000 description 8
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 8
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000002092 calcimimetic effect Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 230000001126 calcilytic effect Effects 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 3
- 102100036893 Parathyroid hormone Human genes 0.000 description 3
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229920003084 Avicel® PH-102 Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- BQIKRTGTPBOIMK-UHFFFAOYSA-N [O]C[O] Chemical compound [O]C[O] BQIKRTGTPBOIMK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 1
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 229940123613 Calcium receptor antagonist Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003075 Plasdone™ K-29/32 polymer Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50221903P | 2003-09-12 | 2003-09-12 | |
| PCT/US2004/026732 WO2005034928A1 (en) | 2003-09-12 | 2004-09-10 | Rapid dissolution formulation of a calcium receptor-active compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ545498A true NZ545498A (en) | 2010-04-30 |
Family
ID=34434844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ545498A NZ545498A (en) | 2003-09-12 | 2004-09-10 | Rapid dissolution formulation of a calcium receptor-active compound |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US7829595B2 (https=) |
| EP (8) | EP3395338B1 (https=) |
| JP (3) | JP5026077B2 (https=) |
| KR (1) | KR101332058B1 (https=) |
| CN (1) | CN1946382B (https=) |
| AR (1) | AR045637A1 (https=) |
| AU (1) | AU2004279318C1 (https=) |
| BR (2) | BR122018013029B1 (https=) |
| CA (1) | CA2536487C (https=) |
| CY (5) | CY1119609T1 (https=) |
| DE (1) | DE19164145T1 (https=) |
| DK (6) | DK1663182T4 (https=) |
| EA (1) | EA013425B1 (https=) |
| ES (7) | ES2655435T3 (https=) |
| HR (1) | HRP20130114T4 (https=) |
| HU (5) | HUE043958T2 (https=) |
| IL (1) | IL173737A (https=) |
| IS (1) | IS3027B (https=) |
| MX (1) | MXPA06002616A (https=) |
| MY (1) | MY142046A (https=) |
| NO (1) | NO335739B1 (https=) |
| NZ (1) | NZ545498A (https=) |
| PL (6) | PL2821067T3 (https=) |
| PT (6) | PT3395338T (https=) |
| SG (1) | SG146608A1 (https=) |
| SI (6) | SI3260117T1 (https=) |
| TR (4) | TR201910447T4 (https=) |
| TW (1) | TWI344363B (https=) |
| WO (1) | WO2005034928A1 (https=) |
| ZA (1) | ZA200602710B (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3395338T (pt) | 2003-09-12 | 2019-07-23 | Amgen Inc | Formulação de dissolução rápida de cinacalcet hcl |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| EP1881954B1 (en) * | 2005-05-16 | 2009-09-16 | Teva Pharmaceutical Industries Ltd. | Process for preparing cinacalcet hydrochloride |
| EP1883625A2 (en) * | 2005-05-23 | 2008-02-06 | Teva Pharmaceutical Industries Ltd | Amorphous cinacalcet hydrochloride and preparation thereof |
| JP4638491B2 (ja) * | 2005-05-23 | 2011-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | シナカルセト塩酸塩結晶フォームｉの調製方法 |
| DK1884242T3 (da) | 2005-05-26 | 2013-05-06 | Dainippon Sumitomo Pharma Co | Farmaceutisk sammensætning omfattende lurasidon |
| US8486381B2 (en) | 2005-09-02 | 2013-07-16 | Amgen Inc. | Methods of modulating intestinal fluid balance |
| EP1828098A1 (en) * | 2005-11-22 | 2007-09-05 | Teva Pharmaceutical Industries Ltd | Crystal forms of cinacalcet hci and processes for their preparation |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
| MX2008012061A (es) * | 2006-03-23 | 2008-12-17 | Amgen Inc | Metodos y composiciones para elaborar y utilizar polimorfos de cinacalcet. |
| KR20080011320A (ko) * | 2006-04-27 | 2008-02-01 | 테바 파마슈티컬 인더스트리즈 리미티드 | 시나칼셋 염기의 제조 방법 |
| US7449603B2 (en) * | 2006-04-27 | 2008-11-11 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of cinacalcet base |
| ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
| WO2008000422A1 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | Amorphous form of cinacalcet |
| JP2010501642A (ja) * | 2006-09-01 | 2010-01-21 | テバ ファーマシューティカル インダストリーズ リミティド | カルシウム受容体−活性化合物の固体複合材料 |
| EP1968932A1 (en) * | 2006-11-20 | 2008-09-17 | Teva Pharmaceutical Industries Ltd. | Process for preparing cinacalcet |
| WO2008064202A2 (en) * | 2006-11-20 | 2008-05-29 | Dr. Reddy's Labortories, Ltd. | Modified-release formulations of calcium receptor-active compounds |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| CA2701638A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals Inc. | Pharmaceutical calcimimetics |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| EP2170805B1 (en) * | 2007-06-21 | 2016-03-16 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
| US20090093652A1 (en) * | 2007-08-16 | 2009-04-09 | Michal Rafilovich | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
| US20090275780A1 (en) * | 2008-05-05 | 2009-11-05 | Medichem, S.A. | Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US20120009258A1 (en) * | 2008-09-25 | 2012-01-12 | Ratiopharm Gmbh | Compacted cinacalcet |
| WO2010086129A1 (en) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Inclusion complex comprising cinacalcet and cyclodextrin |
| SI2408750T1 (sl) | 2009-03-20 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti |
| EP2435400A2 (en) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2314286A1 (de) | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
| WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
| JP6245983B2 (ja) * | 2010-08-11 | 2017-12-13 | ドレクセル ユニバーシティ | パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト |
| EP2642980B8 (en) * | 2010-11-23 | 2020-06-03 | Amgen Inc. | Pediatric formulation |
| JP2014508103A (ja) | 2010-11-26 | 2014-04-03 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| WO2012069420A2 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| EP2643292A1 (en) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| JP2014500882A (ja) | 2010-11-26 | 2014-01-16 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| HK1203384A1 (en) * | 2011-12-19 | 2015-12-11 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| EP2804588B1 (en) | 2012-01-17 | 2017-09-06 | Zentiva Saglik Urunleri San. Ve Tic. A.S. | Method for producing cinacalcet compositions for direct tableting |
| EP2819670A1 (en) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| CN102885792A (zh) * | 2012-10-12 | 2013-01-23 | 华润赛科药业有限责任公司 | 盐酸西那卡塞的口服固体速释制剂 |
| DK2730279T3 (en) | 2012-11-09 | 2015-10-26 | K H S Pharma Holding Gmbh | CINACALCETFORMULERINGER immediate release |
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| CA2895881C (en) * | 2012-12-21 | 2020-03-31 | Synthon B.V. | Tablet composition comprising cinacalcet hydrochloride |
| AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| WO2014207691A1 (en) | 2013-06-26 | 2014-12-31 | Jubilant Life Sciences Limited | Disintegrant free composition of cinacalcet |
| EP3116487A1 (en) | 2014-03-14 | 2017-01-18 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical composition of cinacalcet |
| WO2015150944A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| CN104721164B (zh) * | 2015-03-25 | 2017-07-07 | 河北仁合益康药业有限公司 | 一种盐酸西那卡塞薄膜衣片组合物 |
| JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ治療法 |
| JPWO2017170858A1 (ja) | 2016-03-31 | 2019-02-14 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 溶出性に優れた経口製剤 |
| US11331283B2 (en) * | 2017-08-16 | 2022-05-17 | Unichem Laboratories Ltd | Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders |
| US20210030671A1 (en) | 2018-03-30 | 2021-02-04 | Ftf Pharma Private Limited | Liquid dosage forms of cinacalcet or salt thereof |
| US10920483B2 (en) | 2018-10-25 | 2021-02-16 | Mark Mutchnik | Window seal for preventing water penetration |
| RU2750761C2 (ru) * | 2019-09-17 | 2021-07-02 | Общество с ограниченной ответственностью "АМЕДАРТ" | Ядро таблетки, содержащей цинакальцета гидрохлорид |
| AU2021226416A1 (en) * | 2020-02-29 | 2022-09-15 | Zevra Therapeutics, Inc. | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
| CN112546010A (zh) * | 2020-12-02 | 2021-03-26 | 普莱赛思(天津)生命科技有限公司 | 一种肾病药物组合物及其制备方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517179A (en) | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| NZ226696A (en) | 1987-11-02 | 1991-10-25 | Merck & Co Inc | Tablet composition comprising a phthalazine acetic acid derivative as the active ingredient present in from 83-88 wt% |
| EP0357815A1 (de) | 1988-09-06 | 1990-03-14 | Siemens Aktiengesellschaft | Schaltbare Konstantstromquelle mit I2L-Gattern |
| ZA899071B (en) | 1988-11-30 | 1990-08-29 | Schering Corp | Sustained release diltiazem formulation |
| NZ231897A (en) | 1988-12-30 | 1992-09-25 | Monsanto Co | Dry water-soluble granular composition comprising glyphosate and a liquid surfactant |
| US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US4931286A (en) | 1989-04-19 | 1990-06-05 | Aqualon Company | High gloss cellulose tablet coating |
| DD299322A5 (de) * | 1989-09-21 | 1992-04-09 | Maschinenfabrik Rieter Ag,Ch | Verfahren und vorrichtung zur feinreinigung von textilfasern |
| US5011068A (en) * | 1989-12-05 | 1991-04-30 | Progressive Tool & Industries Co. | Automotive body framing system |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| CN1192011C (zh) | 1991-08-23 | 2005-03-09 | Nps药物有限公司 | 对钙受体具活性的芳烷基胺化合物 |
| ATE313321T1 (de) | 1991-08-23 | 2006-01-15 | Nps Pharma Inc | Kalzium-rezeptor aktive verbindungen |
| US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| DE69333527T2 (de) | 1993-02-23 | 2005-06-16 | Brigham & Women's Hospital, Inc., Boston | Calciumrezeptoraktive moleküle |
| US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| PL181304B1 (pl) * | 1994-07-22 | 2001-07-31 | Lilly Co Eli | Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL |
| ES2285707T3 (es) * | 1994-10-21 | 2007-11-16 | Nps Pharmaceuticals, Inc. | Compuestos activos frente al receptor de calcio. |
| GB9424766D0 (en) | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
| GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| DE19530575A1 (de) | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
| WO1997041090A1 (en) | 1996-05-01 | 1997-11-06 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
| US5837292A (en) | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
| CN1131202C (zh) | 1996-07-08 | 2003-12-17 | 麒麟麦酒株式会社 | 钙受体活性化合物 |
| DE19637082A1 (de) | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
| TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
| IE970588A1 (en) | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
| WO1999009458A1 (de) | 1997-08-13 | 1999-02-25 | OCé PRINTING SYSTEMS GMBH | Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern |
| JP2002505269A (ja) | 1998-03-06 | 2002-02-19 | エウランド インターナショナル ソシエタ ペル アチオニ | 急速崩壊錠剤 |
| US6525084B2 (en) | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
| CA2347092A1 (en) | 1998-10-14 | 2000-04-20 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-disubstituted cyclopropanes |
| WO2000030452A1 (en) | 1998-11-23 | 2000-06-02 | Monsanto Co. | Highly concentrated aqueous glyphosate compositions |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
| CN1434713A (zh) | 1999-12-22 | 2003-08-06 | 法马西亚公司 | 环加氧酶－2抑制剂的缓释制剂 |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| WO2001078725A2 (en) | 2000-04-13 | 2001-10-25 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
| US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| JP2002167327A (ja) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | 固形製剤 |
| AU2001288102A1 (en) | 2000-09-22 | 2002-04-02 | Takeda Chemical Industries Ltd. | Solid preparations |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| IN191028B (https=) | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
| BR0210520A (pt) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros |
| EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| AU2003238670A1 (en) | 2002-04-05 | 2003-10-27 | Cadila Healthcare Limited | Fast disintegrating oral dosage forms |
| US20050147670A1 (en) * | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| WO2004030669A1 (en) | 2002-09-30 | 2004-04-15 | Schering Corporation | Use of tricyclic amides for the treatment of disorders of calcium homeostasis |
| GB0230015D0 (en) | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
| PT3395338T (pt) | 2003-09-12 | 2019-07-23 | Amgen Inc | Formulação de dissolução rápida de cinacalcet hcl |
| EP1930011B1 (en) | 2004-08-23 | 2011-08-17 | Teva Pharmaceutical Industries Ltd | Crystalline form of ibandronate sodium |
| NL1028867C2 (nl) | 2005-04-26 | 2006-10-27 | Xycarb Ceramics B V | Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting. |
| WO2009111876A1 (en) | 2008-03-11 | 2009-09-17 | The University Of Western Ontario | System and method for magnetic resonance imaging |
-
2004
- 2004-09-10 PT PT18175495T patent/PT3395338T/pt unknown
- 2004-09-10 TR TR2019/10447T patent/TR201910447T4/tr unknown
- 2004-09-10 EP EP18175495.3A patent/EP3395338B1/en not_active Revoked
- 2004-09-10 AR ARP040103266A patent/AR045637A1/es unknown
- 2004-09-10 PL PL14163366T patent/PL2821067T3/pl unknown
- 2004-09-10 BR BR122018013029-6A patent/BR122018013029B1/pt active IP Right Grant
- 2004-09-10 TR TR2019/10177T patent/TR201910177T4/tr unknown
- 2004-09-10 PT PT17185704T patent/PT3260117T/pt unknown
- 2004-09-10 DK DK04781429.8T patent/DK1663182T4/da active
- 2004-09-10 PT PT18175499T patent/PT3395340T/pt unknown
- 2004-09-10 NZ NZ545498A patent/NZ545498A/en not_active IP Right Cessation
- 2004-09-10 PT PT18175497T patent/PT3395339T/pt unknown
- 2004-09-10 ES ES14163366.9T patent/ES2655435T3/es not_active Expired - Lifetime
- 2004-09-10 EP EP18175497.9A patent/EP3395339B8/en not_active Revoked
- 2004-09-10 PL PL04781429T patent/PL1663182T5/pl unknown
- 2004-09-10 ES ES19164145T patent/ES2812198T1/es active Pending
- 2004-09-10 MX MXPA06002616A patent/MXPA06002616A/es active IP Right Grant
- 2004-09-10 DK DK14163366.9T patent/DK2821067T3/en active
- 2004-09-10 JP JP2006526096A patent/JP5026077B2/ja not_active Expired - Lifetime
- 2004-09-10 PT PT47814298T patent/PT1663182E/pt unknown
- 2004-09-10 PL PL17185704T patent/PL3260117T3/pl unknown
- 2004-09-10 AU AU2004279318A patent/AU2004279318C1/en not_active Expired
- 2004-09-10 HU HUE17185704A patent/HUE043958T2/hu unknown
- 2004-09-10 SG SG200806469-3A patent/SG146608A1/en unknown
- 2004-09-10 ES ES18175497T patent/ES2735216T3/es not_active Expired - Lifetime
- 2004-09-10 SI SI200432472T patent/SI3260117T1/sl unknown
- 2004-09-10 ES ES18175495T patent/ES2737348T3/es not_active Expired - Lifetime
- 2004-09-10 BR BRPI0414254A patent/BRPI0414254B8/pt active IP Right Grant
- 2004-09-10 PL PL18175499T patent/PL3395340T3/pl unknown
- 2004-09-10 HU HUE18175495 patent/HUE044279T2/hu unknown
- 2004-09-10 DK DK17185704.8T patent/DK3260117T3/da active
- 2004-09-10 EP EP14163366.9A patent/EP2821067B1/en not_active Expired - Lifetime
- 2004-09-10 US US10/937,870 patent/US7829595B2/en active Active
- 2004-09-10 DK DK18175495.3T patent/DK3395338T3/da active
- 2004-09-10 CN CN2004800327959A patent/CN1946382B/zh not_active Expired - Lifetime
- 2004-09-10 KR KR1020067003448A patent/KR101332058B1/ko not_active Expired - Lifetime
- 2004-09-10 SI SI200432473T patent/SI3395339T1/sl unknown
- 2004-09-10 EP EP10014567A patent/EP2316442A1/en not_active Withdrawn
- 2004-09-10 EP EP19164145.5A patent/EP3578175B1/en not_active Revoked
- 2004-09-10 EA EA200600566A patent/EA013425B1/ru unknown
- 2004-09-10 DE DE19164145.5T patent/DE19164145T1/de active Pending
- 2004-09-10 ES ES18175499T patent/ES2735226T3/es not_active Expired - Lifetime
- 2004-09-10 MY MYPI20043684A patent/MY142046A/en unknown
- 2004-09-10 PL PL18175497T patent/PL3395339T3/pl unknown
- 2004-09-10 HU HUE18175499 patent/HUE044822T2/hu unknown
- 2004-09-10 HU HUE14163366A patent/HUE035596T2/en unknown
- 2004-09-10 DK DK18175497.9T patent/DK3395339T3/da active
- 2004-09-10 EP EP04781429.8A patent/EP1663182B2/en not_active Expired - Lifetime
- 2004-09-10 TR TR2019/09267T patent/TR201909267T4/tr unknown
- 2004-09-10 TR TR2019/10180T patent/TR201910180T4/tr unknown
- 2004-09-10 SI SI200432475T patent/SI3395338T1/sl unknown
- 2004-09-10 SI SI200432018T patent/SI1663182T2/sl unknown
- 2004-09-10 DK DK18175499.5T patent/DK3395340T3/da active
- 2004-09-10 HU HUE18175497A patent/HUE045411T2/hu unknown
- 2004-09-10 PL PL18175495T patent/PL3395338T3/pl unknown
- 2004-09-10 EP EP18175499.5A patent/EP3395340B8/en not_active Revoked
- 2004-09-10 ES ES04781429T patent/ES2401769T5/es not_active Expired - Lifetime
- 2004-09-10 TW TW093127508A patent/TWI344363B/zh not_active IP Right Cessation
- 2004-09-10 ES ES17185704T patent/ES2734057T3/es not_active Expired - Lifetime
- 2004-09-10 PT PT141633669T patent/PT2821067T/pt unknown
- 2004-09-10 HR HRP20130114TT patent/HRP20130114T4/hr unknown
- 2004-09-10 EP EP17185704.8A patent/EP3260117B8/en not_active Revoked
- 2004-09-10 CA CA2536487A patent/CA2536487C/en not_active Expired - Lifetime
- 2004-09-10 WO PCT/US2004/026732 patent/WO2005034928A1/en not_active Ceased
- 2004-09-10 SI SI200432474T patent/SI3395340T1/sl unknown
- 2004-09-10 SI SI200432416T patent/SI2821067T1/en unknown
-
2006
- 2006-02-14 IL IL173737A patent/IL173737A/en active IP Right Grant
- 2006-02-23 IS IS8324A patent/IS3027B/is unknown
- 2006-04-03 ZA ZA200602710A patent/ZA200602710B/en unknown
- 2006-04-11 NO NO20061640A patent/NO335739B1/no unknown
-
2010
- 2010-11-09 US US12/942,646 patent/US9375405B2/en active Active
-
2012
- 2012-05-14 JP JP2012110758A patent/JP5849015B2/ja not_active Expired - Lifetime
-
2014
- 2014-08-15 JP JP2014165378A patent/JP5940120B2/ja not_active Expired - Lifetime
-
2016
- 2016-05-24 US US15/163,356 patent/US20160338975A1/en not_active Abandoned
-
2017
- 2017-11-20 CY CY20171101211T patent/CY1119609T1/el unknown
-
2018
- 2018-04-30 US US15/966,812 patent/US20180243238A1/en not_active Abandoned
- 2018-12-20 US US16/227,882 patent/US20190117592A1/en not_active Abandoned
-
2019
- 2019-06-28 CY CY20191100682T patent/CY1122259T1/el unknown
- 2019-07-10 CY CY20191100734T patent/CY1121812T1/el unknown
- 2019-07-10 CY CY20191100735T patent/CY1121814T1/el unknown
- 2019-07-18 CY CY20191100767T patent/CY1121820T1/el unknown
-
2020
- 2020-03-27 US US16/832,087 patent/US20200222340A1/en not_active Abandoned
- 2020-11-06 US US17/091,798 patent/US20210052518A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2536487C (en) | Rapid dissolution formulation of a calcium receptor-active compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 SEP 2017 BY CPA GLOBAL Effective date: 20140731 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2018 BY CPA GLOBAL Effective date: 20170803 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2019 BY CPA GLOBAL Effective date: 20180802 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2020 BY CPA GLOBAL Effective date: 20190801 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2021 BY CPA GLOBAL Effective date: 20200730 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2022 BY CPA GLOBAL Effective date: 20210729 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2023 BY ANAQUA SERVICES Effective date: 20220819 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2024 BY ANAQUA SERVICES Effective date: 20230823 |
|
| EXPY | Patent expired |